Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12428082 | 0.92 | SLC5A2 (1.00) | SLC5A2 | |
| SCHEMBL5273209 | 0.92 | SLC5A2 (1.00) | SLC5A2 | |
| SCHEMBL14590096 | 0.91 | SLC5A2 (1.00) | SLC5A2 | |
| SCHEMBL13513806 | 0.89 | SLC5A2 (1.00) | SLC5A2 | |
| SCHEMBL12387054 | 0.89 | SLC5A2 (1.00) | SLC5A2 | |
| SCHEMBL15270405 | 0.89 | SLC5A2 (1.00) | SLC5A2 | |
| SCHEMBL15981939 | 0.88 | SLC5A2 (0.78) | SLC5A2 | |
| SCHEMBL15284525 | 0.87 | SLC5A2 (0.76) | SLC5A2 | |
| SCHEMBL15298240 | 0.87 | SLC5A2 (0.76) | SLC5A2 | |
| SCHEMBL15272511 | 0.86 | SLC5A2 (1.00) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069374-B2 | CRYSTALLINE SOLVATES OF (1S)-1,5-ANHYDRO-1-C-(3-((PHENYL) METHYL) PHENYL)-D-GLUCITOL DERIVATIVES WITH ALCOHOLS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2021-07-28 | — | — | EP | disclosed |
| CN-108938583-B | Formulations comprising amorphous dapagliflozin | 桑多斯股份公司 | 2021-05-04 | — | — | CN | disclosed |
| US-20190175543-A1 | Formulations Containing Amorphous Dapagliflozin | SANDOZ AG (CH) | 2019-06-13 | — | — | US | disclosed |
| EP-3024442-B1 | FORMULATIONS CONTAINING AMORPHOUS DAPAGLIFLOZIN | SANDOZ AG (CH) | 2019-01-16 | — | — | EP | disclosed |
| US-9453039-B2 | Crystal structures of SGLT2 inhibitors and processes for preparing same | ASTRAZENECA AB (SE) | 2016-09-27 | — | — | US | disclosed |
| US-20160256433-A1 | Formulations Containing Amorphous Dapagliflozin | SANDOZ AG (CH) | 2016-09-08 | — | — | US | disclosed |
| EP-3024442-A1 | FORMULATIONS CONTAINING AMORPHOUS DAPAGLIFLOZIN | Sandoz AG (CH) | 2016-06-01 | — | — | EP | disclosed |
| US-20150307540-A1 | AMORPHOUS FORM OF DAPAGLIFLOZIN 1,2-PROPANEDIOL | CADILA HEALTHCARE LIMITED (IN) | 2015-10-29 | — | — | US | disclosed |
| WO-2015011113-A1 | FORMULATIONS CONTAINING AMORPHOUS DAPAGLIFLOZIN | SANDOZ AG (CH) | 2015-01-29 | — | — | WO | disclosed |
| US-8883743-B2 | Methods for treating obesity employing an SGLT2 inhibitor | ASTRAZENECA AB (SE) | 2014-11-11 | — | — | US | disclosed |
| US-8501698-B2 | Crystal structures of SGLT2 inhibitors and processes for preparing same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-06 | — | — | US | disclosed |
| US-8450286-B2 | Method for treating cancers having high glucose requirements employing an SGLT2 inhibitor and compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120077739-A1 | METHODS FOR TREATING OBESITY EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | BRISTOL-MYERS SQUIBB (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120071403-A1 | Methods for Treating Type 2 Diabetes in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof | ASTRAZENECA UK LIMITED (GB) | 2012-03-22 | — | — | US | disclosed |
| US-8088743-B2 | Methods for treating obesity employing an SGLT2 inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110172176-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-14 | — | — | US | disclosed |
| US-7919598-B2 | Crystal structures of SGLT2 inhibitors and processes for preparing same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-05 | — | — | US | disclosed |
| US-20110015141-A1 | METHOD FOR TREATING CANCERS HAVING HIGH GLUCOSE REQUIREMENTS EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-20 | — | — | US | disclosed |
| US-20080234367-A1 | Sodium dependent glucose transporter (SGLT2); such as dapagliflozin, dapagliflozin-PGS, a C-glucoside or an O-glucoside | BRISTOL-MYERS SQUIBB (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080004336-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160256433-A1 | Formulations Containing Amorphous Dapagliflozin | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885 |
| US-20120077739-A1 | METHODS FOR TREATING OBESITY EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885 |
| US-20110172176-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885 |
| US-20120071403-A1 | Methods for Treating Type 2 Diabetes in Patients Resistant to Previous Treatment with other Anti-Diabetic Drugs Employing an SGLT2 Inhibitor and Compositions Thereof | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885 |
| US-20150307540-A1 | AMORPHOUS FORM OF DAPAGLIFLOZIN 1,2-PROPANEDIOL | SLC5A2, SLC5A1, DPP4 | SLC5A2 1/4885 |
| US-20110015141-A1 | METHOD FOR TREATING CANCERS HAVING HIGH GLUCOSE REQUIREMENTS EMPLOYING AN SGLT2 INHIBITOR AND COMPOSITIONS THEREOF | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885 |
| US-20190175543-A1 | Formulations Containing Amorphous Dapagliflozin | SLC5A2, SLC5A1, SLC2A4 | SLC5A2 1/4885 |
| US-20080234367-A1 | Sodium dependent glucose transporter (SGLT2); such as dapagliflozin, dapagliflozin-PGS, a C-glucoside or an O-glucoside | SLC5A2, SLC5A1, SLC2A1 | SLC5A2 1/4885 |
| US-20080004336-A1 | CRYSTAL STRUCTURES OF SGLT2 INHIBITORS AND PROCESSES FOR PREPARING SAME | SLC5A2, SLC5A1, GLP1R | SLC5A2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.